Oculis Holding AG (FRA:CR5) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:CR5 Oculis Holding AG FRA:CR5
28 GF Score
Price €9.88
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG OCF Margin %?

Oculis Holding AG FRA:CR5 +0.20% 28 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Oculis Holding AG ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Oculis Holding AG's Cash Flow from Operations for the three months ended in Mar. 2026 was €-16.85 Mil. Oculis Holding AG's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Oculis Holding AG's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Oculis Holding AG's current OCF Yield % is -11.27%.

The historical rank and industry rank for Oculis Holding AG's OCF Margin % or its related term are showing as below:


FRA:CR5's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Oculis Holding AG OCF Margin % Related Terms

Oculis Holding AG OCF Margin % Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG OCF Margin % Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:CR5
28GF Score
Oculis Holding AG FRA:CR5
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Oculis Holding AG's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-71.055/0
= %

Oculis Holding AG's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-16.851/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Oculis Holding AG (FRA:CR5) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oculis Holding AG and its competitors. According to the industry distribution chart, Oculis Holding AG ranks #999999 out of 960 companies in the Biotechnology industry.
Is Oculis Holding AG's OCF Margin % too high?
Oculis Holding AG's current OCF Margin % is 0.00%. Based on the distribution chart, Oculis Holding AG ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oculis Holding AG has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's OCF Margin % compare to URGN and SEPN?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #999999 out of 960 companies for OCF Margin %. This places Oculis Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oculis Holding AG and its competitors. Oculis Holding AG's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Oculis Holding AG's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
28GF Score

Get the complete analysis for FRA:CR5

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.88
Price